Sitafloxacin
Encyclopedia
Sitafloxacin is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer
. The molecule was identified by Daiichi Sankyo Co.
, which brought ofloxacin
and levofloxacin
to the market. Sitafloxacin is currently marketed in Japan
by Daiichi Sankyo under the tradename Gracevit.
Buruli ulcer
The Buruli ulcer is an infectious disease caused by Mycobacterium ulcerans. The genus also includes the causative agents of tuberculosis and leprosy...
. The molecule was identified by Daiichi Sankyo Co.
Daiichi Sankyo Co.
is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 970 billion in revenue in 2010 and is currently ranked number 17 in world sales. Its headquarter is based in Tokyo. The company also owns the American biotechnology company Plexxikon, the...
, which brought ofloxacin
Ofloxacin
Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone. The original brand, Floxin, has been discontinued by the manufacturer in the United States on 18 June 2009, though generic equivalents continue to be...
and levofloxacin
Levofloxacin
Levofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class and is used to treat severe or life-threatening bacterial infections or bacterial infections that have failed to respond to other antibiotic classes. It is sold under various brand names, such as Levaquin and...
to the market. Sitafloxacin is currently marketed in Japan
Japan
Japan is an island nation in East Asia. Located in the Pacific Ocean, it lies to the east of the Sea of Japan, China, North Korea, South Korea and Russia, stretching from the Sea of Okhotsk in the north to the East China Sea and Taiwan in the south...
by Daiichi Sankyo under the tradename Gracevit.